A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

NCT04802811 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: SHR2150；Placebo
DRUG: SHR2150；Placebo
DRUG: SHR2150；Placebo
DRUG: SHR2150；Placebo
DRUG: SHR2150；Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.